193 related articles for article (PubMed ID: 26915463)
21. Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
Quinquenel A; Sicre de Fontbrune F; Durot E; Pannetier M; Michonneau D; Socié G; Delmer A; Peffault De Latour R
Br J Haematol; 2017 Mar; 176(6):997-999. PubMed ID: 26991435
[No Abstract] [Full Text] [Related]
22. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Deeks ED
Drugs; 2017 Feb; 77(2):225-236. PubMed ID: 28105602
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
[TBL] [Abstract][Full Text] [Related]
24. The use of ibrutinib in chronic lymphocytic leukemia.
Damon LE
Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
[No Abstract] [Full Text] [Related]
25. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
[No Abstract] [Full Text] [Related]
26. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Manda S; Dunbar N; Marx-Wood CR; Danilov AV
Br J Haematol; 2015 Sep; 170(5):734-6. PubMed ID: 25716177
[No Abstract] [Full Text] [Related]
27. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
28. Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.
Maddy LE; O'Brien DP; Campbell PJ
Intern Med J; 2018 Apr; 48(4):477-479. PubMed ID: 29623996
[No Abstract] [Full Text] [Related]
29. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
[No Abstract] [Full Text] [Related]
30. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
31. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
Rider TG; Grace RJ; Newman JA
Br J Haematol; 2016 Apr; 173(2):326-7. PubMed ID: 26195269
[No Abstract] [Full Text] [Related]
32. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
[No Abstract] [Full Text] [Related]
34. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
35. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
36. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
37. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
Majcherek M; Dworacka M; Dworacki G
Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Molica S
BMC Med; 2017 Aug; 15(1):156. PubMed ID: 28810856
[TBL] [Abstract][Full Text] [Related]
39. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
40. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Wang M; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
